D
Taysha Gene Therapies, Inc. TSHA
$5.09 $0.316.49% NASDAQ
Recommendation
Prev Close
$4.78
Volume
2,450,763
Avg Vol (90D)
5,370,588
Market Cap
$1.31B
Dividend & Yield
--
52-Week Range
$1.05 - $6.02
P/E (TTM)
--
EPS (TTM)
-$0.33
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Is Taysha (TSHA) Balancing TSHA-102 Trial Progress and New Equity Shelf in a Sustainable Way?
1/18/2026 - Simply Wall St
Taysha Gene Therapies (TSHA, $4.56) Stochastic Oscillator left the oversold zone on January 16, 2026
1/17/2026 - Tickeron - Stocks
Taysha Gene Therapies (TSHA, $4.9) price exceeded its 50-day Moving Average on January 15, 2026
1/16/2026 - Tickeron - Stocks
A Look At Taysha Gene Therapies (TSHA) Valuation After Key TSHA-102 Rett Syndrome Trial Milestones
1/16/2026 - Simply Wall St
Sukumar Nagendran Sells 200,000 Shares of Taysha Gene Therapies (NASDAQ:TSHA) Stock
1/15/2026 - MarketBeat
Insider Selling: Taysha Gene Therapies (NASDAQ:TSHA) Insider Sells 200,000 Shares of Stock
1/14/2026 - MarketBeat
Insider Selling: Taysha Gene Therapies (NASDAQ:TSHA) Insider Sells 200,000 Shares of Stock
1/14/2026 - Ticker Report
Taysha Gene Therapies Inc. (TSHA): A Promising Biotech on Rett Syndrome Drug Prospects
1/14/2026 - Insider Monkey
Taysha Gene Therapies (TSHA, $4.9) price moved above its 50-day Moving Average on January 13, 2026
1/14/2026 - Tickeron - Stocks
Taysha Gene Therapies (TSHA, $4.86) price exceeded its 50-day Moving Average on January 12, 2026
1/13/2026 - Tickeron - Technical Analysis
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.3% - Should You Sell?
1/12/2026 - MarketBeat
Why Taysha Gene Therapies (TSHA) Is Down 5.1% After FDA Alignment On TSHA-102 Safety Data
1/11/2026 - Simply Wall St
Taysha Gene Therapies (TSHA, $4.98) Stochastic Oscillator left the oversold zone on January 09, 2026
1/10/2026 - Tickeron - Stocks
Taysha Gene Therapies (TSHA, $5.14) Stochastic Oscillator left the oversold zone on January 08, 2026
1/9/2026 - Tickeron - Technical Analysis
Assessing Taysha Gene Therapies (TSHA) Valuation After REVEAL Trial Progress And FDA Alignment On TSHA-102
1/8/2026 - Simply Wall St
Taysha Gene Therapies (TSHA, $5.26) Aroon Indicator entered an Uptrend on January 06, 2026.
1/7/2026 - Tickeron - Stocks
Taysha Gene Therapies (NASDAQ:TSHA) Earns Buy Rating from Chardan Capital
1/6/2026 - MarketBeat
Taysha Gene Therapies (TSHA, $4.89) Aroon Indicator entered an Uptrend on January 05, 2026.
1/6/2026 - Tickeron - Stocks
Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett ...
1/6/2026 - GuruFocus
Taysha Gene Therapies (TSHA) Advances in Rett Syndrome Gene Therapy Trials
1/6/2026 - GuruFocus
Taysha Gene Therapies announces progress across TSHA-102
1/6/2026 - The Fly
Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome
1/6/2026 - Globe Newswire
Taysha Gene Therapies (NASDAQ:TSHA) Cut to Sell at Wall Street Zen
1/6/2026 - Ticker Report
Taysha Gene Therapies price target raised by $3 at Wells Fargo, here's why
1/5/2026 - The Fly
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Moderate Buy" from Analysts
1/5/2026 - MarketBeat
Income Statement
Total Revenue (TTM)
$6.31M
EBITDA (TTM)
-$100.98M
EBIT (TTM)
-$102.13M
Net Income (TTM)
-$99.93M
Balance Sheet
Total Assets (Q)
$316.55M
Total Debt (Q)
$69.08M
Total Liabilities (Q)
$97.57M
Book Value Per Share (Q)
$0.7995
Cash Flow
Cash from Operations (TTM)
-$84.68M
Cash from Investing (TTM)
-$344.00K
Cash from Financing (TTM)
$224.68M
Net Change in Cash (TTM)
$139.66M
Filings
Filing Date
Tuesday, November 4, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 23 and 27 (est)
Price History
Loading...
Beta
3.56
7-Day Total Return
4.73%
30-Day Total Return
-6.61%
60-Day Total Return
7.16%
90-Day Total Return
65.80%
Year to Date Total Return
-3.05%
1-Year Total Return
232.68%
2-Year Total Return
241.61%
3-Year Total Return
167.89%
5-Year Total Return
-83.48%
52-week Low
Apr 09, 2025 - $1.05
52-week High
Dec 24, 2025 - $6.02
Valuation
Market Cap
$1.31B - Small Cap
Enterprise Value
$1.08B
Price/Sales (TTM)
268.54
Price/Book (Q)
5.98
Dividends and Shares
Shares Outstanding
353.31M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.tayshagtx.com
Phone Number
214 612 0000
Address
3000 Pegasus Park Drive
Dallas, TX 75247
Country
United States
Year Founded
2019
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases... more
NASDAQ 01/22/2026 4:00PM Eastern Quotes delayed